Oncolytics Biotech (ONCY) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts ONCY Hot Sheet
Join SI Premium – FREE
Oncolytics Biotech (NASDAQ: ONCY) reported Q2 EPS of ($0.05), $0.02 better than the analyst estimate of ($0.07).
For earnings history and earnings-related data on Oncolytics Biotech (ONCY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- UBS Reiterates Neutral Rating on Newell Brands Inc (NWL)
- StoneX Reiterates Hold Rating on Meta Platforms Inc. (META) as Strategy Lacks Quantified Returns, Product Economics
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
